1. Home
  2. REED vs SNGX Comparison

REED vs SNGX Comparison

Compare REED & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reed's Inc.

REED

Reed's Inc.

N/A

Current Price

$0.77

Market Cap

9.1M

Sector

N/A

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$0.36

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REED
SNGX
Founded
1987
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.6M
IPO Year
2009
2006

Fundamental Metrics

Financial Performance
Metric
REED
SNGX
Price
$0.77
$0.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 2.6M
104.9K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.03
EPS
N/A
★ N/A
Revenue
★ $34,065,000.00
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
$27.29
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.33
$0.32
52 Week High
$5.97
$3.39

Technical Indicators

Market Signals
Indicator
REED
SNGX
Relative Strength Index (RSI) 57.78 36.40
Support Level $0.72 $0.32
Resistance Level $1.04 $0.82
Average True Range (ATR) 0.17 0.02
MACD 0.04 0.01
Stochastic Oscillator 54.63 64.02

Price Performance

Historical Comparison
REED
SNGX

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: